Elaine Hochberg

Elaine Hochberg, Executive Vice President and Chief Commercial Officer of Forest Laboratories Inc., has steered the company toward unprecedented growth since 1997. Helping raise revenues to $4.4 billion in fiscal year 2011, Elaine Hochberg has also assisted in building the company’s workforce to 5,300 employees, including a national sales force of 3,000 representatives.

After working for many years in Forest Laboratories’ Marketing and Managed Markets sections, Elaine Hochberg advanced to her current position in 2010. Hochberg currently leads the publicly traded company’s entire Commercial Operations organization, including the General Field Sales Force and the Trade and Institutional Sales Groups.

Elaine Hochberg has guided the company in the launch of multiple successful products over the past 10+ years. . Embodying the company’s philosophy, Hochberg concentrates on marketing and selling products for medical conditions for which there is an unmet medical need.

Elaine Hochberg has helped direct the 50-plus year-old company during the most productive time in its history. In 1998, she launched Celexa, a highly successful antidepressant that led to immense company growth. Most recently, in 2011, she directed the launches of three new drugs within just six months: Teflaro® (ceftaroline fosamil), Daliresp™ (roflumilast) and Viibryd™ (vilazodone HCl). Additional products launched under Ms. Hochberg’s leadership include:

▪ Azor® (amlodipine and olmesartan medoxomil)

▪ Benicar® (olmesartan medoxomil)

▪ Benicar HCT® (olmesartan medoxomil - hydrochlorothiazide)

▪ Bystolic® (nebivolol)

▪ Campral® (acamprosate calcium)

▪ Celexa® (citalopram HBr)▪ Combunox® (oxycodone HCl and ibuprofen)

▪ Infasurf® (calfactant)

▪ Lexapro® (escitalopram oxalate)

▪ Namenda® (memantine HCl)

▪ Savella® (milnacipran HCl)

The company’s array of products treats a wide range of ailments that affect millions of patients, including depression, general anxiety disorder, Alzheimer’s disease, pain, bacterial infections, respiratory disorders, and fibromyalgia.